Early anti-TNF treatment in pediatric Crohn’s disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients

References

• Hanauer S, Feagan B, Lichtenstein G, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 2002;359:1541–9.
   PubMed Web of Science ®Google Scholar
• Sands FH, Anderson CN, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876–85.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004;126:402–13.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr 2000;137:192–6.
   PubMed Web of Science ®Google Scholar
• Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 2007;67:1703–23.
   PubMed Web of Science ®Google Scholar
• de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:3–14.
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007;132:863–73.
   PubMed Web of Science ®Google Scholar
• Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis 2012;30:67–72.
   PubMed Web of Science ®Google Scholar
• Crocco S, Martelossi S, Giurici N, Villanacci V, Ventura A. Upper gastrointestinal involvement in paediatric onset Crohn's disease: prevalence and clinical implications. J Crohns Colitis 2012;6:51–5.
   PubMed Web of Science ®Google Scholar
• Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm Bowel Dis 2007;13:424–30.
   PubMed Web of Science ®Google Scholar
• D'Haens G. Mucosal healing in pediatric Crohn’s disease: the goal of medical treatment. Inflamm Bowel Dis 2004;10:479–80.
   PubMed Web of Science ®Google Scholar
• Vatn MH. Mucosal healing: impact on the natural course or therapeutic strategies. Dig Dis 2009;27:470–5.
   PubMed Web of Science ®Google Scholar
• Borrelli O, Bascietto C, Viola F. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 2004;36:342–7.
   PubMedGoogle Scholar
• Perminow G, Brackmann S, Lyckander LG, Franke A, Borthne A, Rydning A, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005-07, showing increased incidence in Crohn’s disease. Scand J Gastroenterol 2009;44:446–56.
   PubMed Web of Science ®Google Scholar
• Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine JE, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8–15.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibor PM, Kirschner B, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439–47.
   PubMed Web of Science ®Google Scholar
• Tanner JM, Whitehouse RH, Takasshi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Arch Dis Child 1966;41:454–71.
   PubMed Web of Science ®Google Scholar
• Fagerberg UL, Loof L, Lindholm J, Hansson L-O, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:414–20.
   PubMed Web of Science ®Google Scholar
• Escher JC, Dias JA, Bochenek K, Buderus S, de Mesquita MB, Bujanover Y and the IBD Working Group of ESPGHAN. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1–7.
   PubMed Web of Science ®Google Scholar
• Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60:505–12.
   PubMed Web of Science ®Google Scholar
• Froesli KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease. Gastroenterology 2007;133:412–22.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Strobel SG, Deshpande AR, Abreu MT. Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2011;7:652–9.
   PubMedGoogle Scholar
• Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, Dé Angelis GL, et al. Response to infliximab is related to disease duration in pediatric Crohn's disease. Aliment Pharmacol Ther 2003;18:425–31.
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 2000;95:3189–94.
   PubMed Web of Science ®Google Scholar
• Hyams JC, Lerer T, Griffith A, Pfefferkorn M, Kugathasan S, Evans J, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009;15:816–22.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–95.
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895–902.
   PubMed Web of Science ®Google Scholar
• Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol 2012;18:3790–9.
   PubMed Web of Science ®Google Scholar
• Ushiku T, Moran CJ, Lauwers G. Focally enhanced gastritis in newly diagnosed Pediatric Inflammatory Bowel Disease. Am J Surg Pathol 2013;37:1882–8.
   PubMed Web of Science ®Google Scholar
• Annunziata ML, Caviglia R, Papparella LG, Cicala M. Upper gastrointestinal involvement of Crohn's disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci 2012;57:1618–23.
   PubMed Web of Science ®Google Scholar
• Turner D, Griffith AM. Esophageal, gastric, and duodenal manifestations of IBD and the role of upper endoscopy in IBD diagnosis. Curr Gastroenterol Rep 2007;9:475–8.
   PubMedGoogle Scholar
• Hummel TZ, ten Kate FJ, Reitsma JB, Benninga MA, Kindermann A. Additional value of upper GI tract endoscopy in the diagnostic assessment of childhood IBD. J Pediatr Gastroenterol Nutr 2012;54:753–7.
   PubMed Web of Science ®Google Scholar
• Sharif F, McDermott M, Path MRC, Drumm B, Rowland M, Imrie C, et al. Focally enhanced gastritis in children with Crohn’s disease and ulcerative colitis. Am J Gastroenterol 2002;97:1415–20.
   PubMed Web of Science ®Google Scholar
• Castellaneta SP, Afzal NA, Greenberg M, Deere H, Davies S, Murch SH, et al. Diagnostic Role of Upper Gastrointestinal Endoscopy in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2004;39:257–61.
   PubMed Web of Science ®Google Scholar
• Kovascs M, Muller KE, Arato A, Lakatos PL, Kovacs JB, Varkonyi A, et al. Diagnostic yield of upper endoscopy in paediatric patients with Crohn’s disease and ulcerative colitis. J Crohns Colitis 2012;6:86–94.
   PubMed Web of Science ®Google Scholar
• Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn’s disease. Evidence for and against current therapies. Aliment Pharmacol Ther 2007;25:3–12.
   PubMed Web of Science ®Google Scholar
• Van Limbergen J, Russel RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic charachteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114–22.
   PubMed Web of Science ®Google Scholar
• Vernier–Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology 2008;135:1106–11.
   PubMed Web of Science ®Google Scholar